Figure 1



Proportion of subjects free of relapse
100
80
60
40
20
0
Q1M
Hazard Ratio (95% CI) 0.200 (0.109, 0.367)
log rank test p-value <.0001
Q2M
Hazard Ratio (95% CI) 0.375 (0.227, 0.618)
log rank test p-value <.0001
0 28 56 84 112 140 168 196 224 252 280 308 336 364 392 420 448 476 504 532 560 588 616 644 672 700
Days from randomization
Placebo Q1M Q2M
Placebo 181 163 148 122 110 99 90 79 71 64 59 51 40 36 29 24 18 14 13 11 7 6 4 3 1 0
Q1M 183 178 169 156 144 131 124 112 106 94 89 77 68 61 54 45 41 34 27 21 18 15 11 7 3 1
Q2M 179 168 148 137 127 119 115 103 94 83 75 67 61 54 45 40 36 29 25 19 16 9 7 4 2 2

Figure 2



LS Mean +/- SE
Baseline
Analysis Visit
Placebo
Q1M
Q2M
Week 4
Week 8
Week 12
Week 16
Week 20
Week 24
Week 28
Week 32
Week 36
Week 40
Week 44
Week 48
Week 52
Week 56
Week 60
Week 64
Placebo 157 136 115 105 94 84 72 64 58 51 41 37 32 24 19 15
Q1M 171 163 147 136 126 118 107 95 89 78 69 61 54 46 41 35
Q2M 156 145 130 124 114 103 94 85 75 68 63 54 46 41 37 31

Figure 3A




90% Prediction Interval
Median of Simulations
50 Q1M
75 Q1M
100 Q1M
125 Q1M
Total Active Moiety Concentration (ng/mL)
100
30
10
3
0
28
56
84
112
140
Time Since First Dose (Day)
90% Prediction Interval
Median of Simulations
100 Q2M
150 Q2M
200 Q2M
250 Q2M
Total Active Moiety Concentration (ng/mL)
100
10
1
0
56
112
168
224
280
Time Since First Dose (Day)

Figure 3B


Risperidone
9-OH Risperidone
Prediction corrected plasma concentrations (ng ml^{-1})
100
10
1
0.1
0 10 20 30 40 50 60
Time after dose (days)